Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies1
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries have launched a novel anti-cancer drug, Palbociclib in India for patients who have advanced breast cancer, the most common cancer among women in the country. The company will make the drug available under the brand name, PALENOTM (Palbociclib) 75 mg, 100 mg, 125 mg.
Kirti Ganorkar, CEO – India Business, Sun Pharma, said “We are introducing Palbociclib at an affordable price which will help improve patient access. PALENOTM will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance program that will improve patient compliance and accessibility.”
Palbociclib is approved by the US FDA, EMA and CDSCO in combination with hormonal therapies for patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer.
